$4.13
84.40% yesterday
Nasdaq, Nov 25, 09:48 pm CET
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Cassava Sciences, Inc. Stock price

$4.30
-22.26 83.82% 1M
-17.42 80.22% 6M
-18.22 80.92% YTD
-16.91 79.74% 1Y
-53.76 92.60% 3Y
+2.89 204.61% 5Y
-8.80 67.19% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-22.19 83.78%
ISIN
US14817C1071
Symbol
SAVA
Sector
Industry

Key metrics

Market capitalization $206.63m
Enterprise Value $17.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.24
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-141.65m
Free Cash Flow (TTM) Free Cash Flow $-78.07m
Cash position $188.98m
EPS (TTM) EPS $-1.37
P/E forward negative
Short interest 41.31%
Show more

Is Cassava Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Cassava Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Cassava Sciences, Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Cassava Sciences, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Cassava Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.23 1.23
21% 21%
-
-1.23 -1.23
21% 21%
-
- Selling and Administrative Expenses 71 71
465% 465%
-
- Research and Development Expense 68 68
23% 23%
-
-140 -140
37% 37%
-
- Depreciation and Amortization 1.23 1.23
21% 21%
-
EBIT (Operating Income) EBIT -142 -142
36% 36%
-
Net Profit -18 -18
81% 81%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cassava Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cassava Sciences, Inc. Stock News

Negative
Fast Company
about 2 hours ago
In March, pharmaceutical company Cassava Sciences made headlines for a report by the Food and Drug Administration (FDA) that cast doubt on the positive trial results of its novel Alzheimer's drug, simufilam.
Negative
Invezz
about 19 hours ago
Cassava Sciences (SAVA), the Austin-based biotech firm specializing in neurodegenerative diseases, suffered a major blow on Monday when its stock plunged 85%. The sharp drop came after the company announced that its Phase 3 clinical trial for simufilam, an experimental Alzheimer's treatment, failed to meet its primary endpoints.
Negative
Investors Business Daily
about 21 hours ago
Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. The post Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops appeared first on Investor's Business Daily.
More Cassava Sciences, Inc. News

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Head office United States
CEO Richard Barry
Employees 29
Founded 1998
Website www.cassavasciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today